Anisomycin

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

一种通过抑制肽基转移酶或 80S 核糖体系统来抑制真核蛋白质合成的抗生素。

An antibiotic that inhibits eukaryotic protein synthesis by inhibiting peptidyl transferase or the 80S ribosome system; sensitizes RCC cells to DR4-mediated apoptosis through the induction of DR4.(In Vitro):To examine whether JNK has a core role in colistin-induced neurotoxicity in PC-12 cells, an SP600125 (a highly selective inhibitor of JNK) and Anisomycin (a potent activator) are used in this study. In order to select an appropriate concentration, PC-12 cells are treated with a range of SP600125 (0-80 μM) and Anisomycin (0-20 μM) respectively for 24 h. The results show that the cells viability significantly decreases by SP600125 treatment in a concentration-dependent manner, observed at the concentrations greater than 20 μM (p<0.01). Similarly the cells viability is inhibited by Anisomycin treatment (≥8 μM) (p<0.05) .(In Vivo):Anisomycin (60 mg/kg; for 4-week continuous intravenous administration) significantly decreases mouse body weight in a dose-related manner, compared with the control group. Anisomycin (15 mg/kg; for 4-week continuous intravenous administration) slightly and transiently decreases the mouse body weight. There is no significant difference of the mouse body weight in 5 mg/kg group.

To examine whether JNK has a core role in colistin-induced neurotoxicity in PC-12 cells, an SP600125 (a highly selective inhibitor of JNK) and Anisomycin (a potent activator) are used in this study. In order to select an appropriate concentration, PC-12 cells are treated with a range of SP600125 (0-80 μM) and Anisomycin (0-20 μM) respectively for 24 h. The results show that the cells viability significantly decreases by SP600125 treatment in a concentration-dependent manner, observed at the concentrations greater than 20 μM (p<0.01). Similarly the cells viability is inhibited by Anisomycin treatment (≥8 μM) (p<0.05) .

Anisomycin (60 mg/kg; for 4-week continuous intravenous administration) significantly decreases mouse body weight in a dose-related manner, compared with the control group. Anisomycin (15 mg/kg; for 4-week continuous intravenous administration) slightly and transiently decreases the mouse body weight. There is no significant difference of the mouse body weight in 5 mg/kg group. Animal Model:Balb/c mice of both sexes (4-5 weeks old)Dosage:84, 99, 116, 136 or 160 mg/kg; 0.2 mL per mouse Administration:Intravenously injected through mouse tail vein Result:The calculated LD50 for Anisomycin was 119.64 mg/kg.

Flagecidin | Wuningmeisu C

GPCR/G Protein

Antibacterial

JNK

Infection

——

22862-76-6

265.305

C14H19NO4

>98% (HPLC)

10 mM in DMSO

O[C@@H]1[C@@H](OC(C)=O)[C@@H](CC2=CC=C(OC)C=C2)NC1

3,4-Pyrrolidinediol, 2-[(4-methoxyphenyl)methyl]-, 3-acetate, (2R,3S,4S)-

(-20℃)

With Ice Pack

≥ 2 years